Recent studies have shown that DUX4 rearrangements are associated with a favorable prognosis of pediatric ALL, whereas ZNF384 rearrangements appear to be associated with an intermediate outcome. This evidence concerns the gene DUX4 and acute lymphoblastic leukemia.